Showing results (31-40 of 145) with videos related to
Sort By:
Pageof 15
Epidemiology (Cambridge, Mass.)|August 19, 2007
Estimating the effects of time-varying treatments: incidence of fractures among postmenopausal Japanese womenShiro Tanaka, Yutaka Matsuyama, Masataka Shiraki, et al.Geriatrics & Gerontology International|May 15, 2024
Serum branched-chain amino acid levels are associated with fracture risk in Japanese womenTomohiko Urano, Tatsuhiko Kuroda, Kazuhiro Uenishi, et al.Osteoporosis and Sarcopenia|February 19, 2019
Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countriesAkira Taguchi, Masataka Shiraki, Archie Morrison, et al.Menopause (New York, N.Y.)|November 6, 2019
Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trialAkira Taguchi, Masataka Shiraki, Satoshi Tanaka, et al.Journal of Clinical Pharmacology|November 2, 2020
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic AcidHidefumi Kasai, Yoko Mori, Atsushi Ose, et al.Journal of Bone and Mineral Metabolism|June 20, 2019
The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal womenMasataka Shiraki, Shoji Kashiwabara, Takumi Imai, et al.Calcified Tissue International|June 25, 2013
Plasma level of homocysteine associated with severe vertebral fracture in postmenopausal womenTatsuhiko Kuroda, Shiro Tanaka, Mitsuru Saito, et al.Journal of Bone and Mineral Metabolism|August 21, 2013
Low calcium intake is associated with high plasma homocysteine levels in postmenopausal womenShiro Tanaka, Kazuhiro Uenishi, Yasushi Yamazaki, et al.Journal of Bone and Mineral Metabolism|December 22, 2016
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosisMasataka Shiraki, Satoshi Tanaka, Hiroaki Suzuki, et al.Current Medical Research and Opinion|January 8, 2014
Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatideShiro Tanaka, Tatsuhiko Kuroda, Toshitsugu Sugimoto, et al.Pageof 15